Piroxicam

Piroxicam is a non-selective COX inhibitor. (In Vitro) :Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells. (In Vivo) :Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration.